FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2007

FERMAVIR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)


Florida	333-116480	16-1639902
(State of Incorporation)	(Commission File Number)	(IRS Employer
		Identification No.)

420 Lexington Avenue, Suite 445
New York, New York 10170
(Address of Principal Executive Offices)


(212) 413-0802
(Registrant’s telephone number, including area code)

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.24d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.23e-4(c))

Item 4.01 Changes in Registrant’s Certifying Accountant.

On March 26, 2007, J.H. Cohn LLP, resigned as FermaVir Pharmaceuticals, Inc.’s (the “Company”) principal accountants which was reported on Form 8-K/A filed on March 30, 2007. On June 29, 2007, the Company engaged BDO Seidman, LLP (“BDO”) as its principal independent registered public accounting firm. The Company’s audit committee has approved the appointment of BDO as the Company’s new principal independent registered public accounting firm.

Prior to engaging BDO the Company did not consult with them regarding either:

1. the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered in the Company’s financial statements, and neither a written report was provided to the Company nor oral advice was provided that BDO concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or

2. any matter that was either subject of disagreement or event, as defined in Item 304(a)(1)(iv)(A) of Regulation S-K and the related instruction to Item 304 of Regulation S-K, or a reportable event, as that term is explained in Item 304(a)(1)(iv)(A) of Regulation S-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 2, 2007


	FERMAVIR PHARMACEUTICALS, INC.


	By:	/s/	Geoffrey W. Henson
			Geoffrey W. Henson
			Chief Executive Officer

FERMAVIR PHARMACEUTICALS, INC. 8-K